This activity is designed for an audience of of Cardiologists, Lipidologists, Endocrinologists, physician assistants, nurses and other cardiometabolic specialists. A secondary audience of primary care providers is targeted based on real world shortages of specialized clinicians.

All of the relevant financial relationships have been mitigated. It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

	William Virgil Brown, MD Has affiliations with: Amgen – Data Monitor for Clinical Trial, Esperion. Data Monitor for Clinical Trial.
	Eugene Braunwald, MD Has disclosed no financial relationships.
	Marina Cuchel, MD, PhD Served as an advisor or consultant for: Amryt Pharma, Received grants for clinical research from: Regeneron; Regenxbio.
	Erin Donnelly Michos, MD, MHS Medical Advisory Boards for Esperion, Amarin, Novartis, and AstraZeneca.
	Keith C. Ferdinand, MD, FACC, FAHA  Consultant:  Amgen, Sanofi, Boehringer Ingelheim, Novartis, Quantum Genomics.
	Jean-Charles Fruchart, PharmD, PhD  Speakers’ Bureau for Solvay, Astra Zeneca UK, and Sanofi-Aventis. Professor Fruchart is a cofounder and President of the supervisory board of Genfit and serves as a consultant to Fournier Laboratories, Ltd., Astra Zeneca, Kowa Company, Ltd., and Pfizer Inc.
	Henry N Ginsberg, MD Has affiliations with: Consulting: Merck, Silence Therapeutics, Kowa, AstraZeneca, Janssen, Sanofi, Resverlogix. Research Grant: Pfizer, Amgen, Medimmune/AstraZeneca.
	Antonio M. Gotto, Jr, MD, DPhil, FACC, has affiliations with:  Member, Board of Directors -Esperion Therapeutics Consultant – Amarin, Kowa;  Data and Safety Monitoring Board – Ionis Pharmaceuticals Chair.
	Heiner Greten, MD has disclosed no financial relationships.
	Lawrence A Leiter, MD has disclosed no financial relationships.
	Peter Libby, MD has affiliations with: research funding in the last 2 years from Novartis. Dr. Libby is on the Board of Directors of XBiotech, Inc. Dr. Libby has a financial interest in Xbiotech.
	Alice H. Lichtenstein, DSc has disclosed no financial relationships.
	Alberto J. Lorenzatti, MD, MTFAC, FACC  Grants from Amgen, Novo-Nordisk and Resverlogix.
	Samia Mora, MD, MHS, FACC Consulting Fees/Honoraria: Medtelligence; Research/Research Grants: Kowa Research Institute, Denka Seiken.
	Stephen Nicholls, MBBS, PhD  Received grants for clinical research from: Anthera Pharmaceuticals, Inc., AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; LipoScience Inc.;Novartis Pharmaceuticals Corporation; Resverlogix Corp.; Roche.  Served as an advisor or consultant for: Abbott Laboratories; Anthera Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Merck & Co., Inc.; Pfizer Inc.; Roche; Takeda Pharmaceuticals North America, Inc.
	Borge Nordestgaard, MD, DMSc has affiliations with: Consultancies and talks sponsored by AstraZeneca, Sanofi, Regeneron, Akcea, Amgen, Kowa, Denka Seiken, Amarin, Novartis, Novo Nordisk, Esperion, and Silence Therapeutics.
	Chris J Packard, CBE, FRSE has affiliations with:  Adviser Dalcor and Merck Inc: Honoraria Amgen and Daiichi-Sankyo.
	Terje Pedersen, MD has affiliations with:  Research Grants and/or Speaker/Consultant fees from Merck, MSP, Astra-Zeneca, and Pfizer.
	Aruna D. Pradhan, MD, MPH, MSc Has disclosed no financial relationships.
	Paul M. Ridker, MD, MPH  Consultant Fees/Honoraria:  Agepha, AstraZeneca, Boston Pharma, Civi Biopharm, Corvidia, Flame, Inc., Inflzome, IQVIA, Janssen Pharmaceuticals, Novartis, Novo Nordisk, Omeicos, Simanomics. Research/Research Grants:  Amarin, Kowa Pharmaceuticals, Novartis.
	Frank Sacks, MD has affiliations with: Consultant – AstraZeneca, Cor2Ed, CSL, Pfizer, Terra Firma;  Expert testimony- AbbVie and Pfizer.
	Raul D Santos, MD, MSc, PhD has affiliations with:  Honoraria/Consultant – Abbott, Ache, Astra Zeneca, Amgen, Esperion, GETZ Pharma, Kowa, Merck, Pfizer, PTC Therapeutics, Novartis, Novo-Nordisk, Sanofi.
	Allan Sniderman, MD, FRCP(C), FRSC has disclosed no financial relationships.
	Erik Stroes MD has affiliations with: Ad-board/lecturing fees paid to institution – Amgen, Esperion, Ionis, Novartis, Novo-Nordisk, Sanofi.
	Anne Tybjærg-Hansen, MD DMSc has affiliations with: Consultancies or talks for Akcea, Astra Zeneca, Regeneron, Sanofi, Novartis, Draupnir Bio, and Silence Therapeutics.
	Sotirios (Sam) Tsimikas, MD, FACC has affiliations with:  Ownership/Partnership/Principal: Oxitope, Inc, Kleanthi Diagnostics; Salary: Ionis Pharmaceuticals.
	Peter F.W. Wilson, MD has disclosed no financial relationships.
	Salim S. Virani, MD, PhD, FACC, FAHA has disclosed no financial relationships.
	Dong Zhao, MD, PhD has disclosed no financial relationships.

Staff Disclosures

Dorothy Caputo, MA, BSN, RN, AKH CE Director of Accreditations: has disclosed no financial relationships.

Patricia Brignoni, AKH Director of Operations/Reviewer: has disclosed no financial relationships.

AKH Inc. and IAS planners and reviewers disclosed no financial relationships

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and International Atherosclerosis Society (IAS). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 7 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
7 ANCC contact hours

Physicians Assistants
AAPA Credit Designation Statement
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 7 AAPA Category 1 CME credits. Approval is valid until August 31, 2022. PAs should only claim credit commensurate with the extent of their participation.

Upon completion of the educational activity, participants should be able to:

• Discuss the origins of common blood cholesterols concentrations commonly seen.
• Discuss the origins of other major risk factors that lead to ASCVD.
• Describe the impact of diet and lifestyle and the recommendations to consider in the prevention of ASCVD.
• Examine the benefit of new drugs derived from understand the mechanisms of these diseases and proof of benefit shown in clinical trials.
• Defining the Overweight/Obese Patient Relationship to Obesity and CV risk
• Review of dietary components that raise LDL-C and/or non-HDL-C.
• Review of dietary components that raise Triglycerides and or lower HDL-C.

Criteria for Success
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at https://iasec.regionglobal.com/courses/essentials-of-residual-risk/.

CLAIM CREDIT WILL NOT OPEN UNTIL August 1, 2021.

Commercial Support
This activity is supported by educational grants from Amarin Corporation, Amryt Pharma, Novartis, Novo Nordisk, Merck & Co., and Sanofi.